ClinicalTrials.gg
CompletedNCT03036241DRECOREST2Updated Jun 23, 2017

Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis (Dialysis Fistulae)

An interventional study of Conventional angioplasty and Angioplasty with drug-eluting balloon in Vascular Access Complication, Restenosis, Vascular Graft and Dialysis Related Complications, sponsored by Helsinki University Central Hospital. Completed. Per ClinicalTrials.gov, last updated 2017-06-23.

Sponsored by Helsinki University Central Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 11 months after the study started (first participant enrolled Jan 2013, registered Jan 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Randomized
Sex
All
01

Study summary

The purpose of this study is to determine whether the use of drug-eluting balloons is effective in the treatment of (re)stenosis in dialysis fistulae.

Read the detailed description

Drug-eluting devices have proved beneficial in the treatment of stenosis in native coronary and lower limb arteries. Stenosis and restenosis is a known problem in dialysis fistulae and drug-eluting devices might be beneficial in this field as well.

In the procedure a conventional balloon is passed through the stenosis which is then dilated. After this patients are randomized before a second dilatation with either a conventional balloon or a drug-coated balloon.

The stenosis is evaluated preoperatively and followed up by means of ultrasound by a vascular technician. Follow-up will end at 12 months.

02

Conditions studied

  • Vascular Access Complication
  • Restenosis, Vascular Graft
  • Dialysis Related Complications

Keywords

  • drug-eluting balloon,
  • target lesion revascularization (TLR)
  • restenosis
03

In context

Lead sponsor

Helsinki University Central Hospital is the lead sponsor of 311 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any dialysis access w/ native vessels warranting intervention

Exclusion criteria

Exclusion Criteria:

  • Previous PTA with drug-eluting balloon, thrombolysis, coagulopathy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Drug-eluting balloon

    Device: Angioplasty with drug-eluting balloon

  • Active comparator
    Conventional angioplasty

    Device: Conventional angioplasty

Interventions

  • DeviceConventional angioplasty

    Angioplasty with conventional balloon

    Also known as: PTA

  • DeviceAngioplasty with drug-eluting balloon

    Angioplasty with drug-eluting balloon

    Also known as: DEB

06

What researchers measure

Primary outcomes

  1. TLR

    Target lesion revascularization, ie. re-intervention to the same lesion

    Time frame: 12 months

  2. Occlusion of access

    Any loss of dialysis access due to thrombosis

    Time frame: 12 months

Secondary outcomes

  1. Primary assisted patency

    Patency after endovascular reintervention due to restenosis or thrombosis

    Time frame: 12 months

  2. Death

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Bjorkman P, Weselius EM, Kokkonen T, Rauta V, Alback A, Venermo M. Drug-Coated Versus Plain Balloon Angioplasty In Arteriovenous Fistulas: A Randomized, Controlled Study With 1-Year Follow-Up (The Drecorest Ii-Study). Scand J Surg. 2019 Mar;108(1):61-66. doi: 10.1177/1457496918798206. Epub 2018 Sep 5. PubMed 30182815 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Feb 2017, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2017
First posted
Jan 30, 2017
StartActual
Jan 23, 2013
Primary completionActual
Feb 28, 2017
CompletionActual
Feb 28, 2017
Last update
Jun 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03036241
Responsible party
Maarit Venermo (Professor of Vascular Surgery, Helsinki University Central Hospital) — Principal investigator
First posted
Jan 30, 2017
Start date
Jan 23, 2013
Primary completion
Feb 28, 2017
Completion
Feb 28, 2017
Last update
Jun 23, 2017

Study contacts

Maarit Venermo, Prof
principal investigator · Helsinki University Hospital, dept of vascular surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion